A detailed history of Grove Bank & Trust transactions in Exact Sciences Corp stock. As of the latest transaction made, Grove Bank & Trust holds 10 shares of EXAS stock, worth $581. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10
Previous 10 -0.0%
Holding current value
$581
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 30, 2024

SELL
$59.06 - $75.72 $5,669 - $7,269
-96 Reduced 90.57%
10 $0
Q3 2023

Oct 30, 2023

SELL
$65.94 - $99.04 $1,450 - $2,178
-22 Reduced 17.19%
106 $7,000
Q4 2022

Feb 03, 2023

BUY
$30.35 - $53.15 $3,884 - $6,803
128 New
128 $6,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Grove Bank & Trust Portfolio

Follow Grove Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grove Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Grove Bank & Trust with notifications on news.